导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -18.11% | 4264/4773 |
| 近一周 | -4.32% | 5085/5465 |
| 近一月 | -3.73% | 2771/5421 |
| 近一季 | 1.08% | 775/5231 |
| 近半年 | -17.88% | 4273/4920 |
| 近一年 | -26.02% | 4112/4394 |
| 近两年 | -2.66% | 2914/2954 |
| 近三年 | -30.11% | 2211/2253 |
| 成立以来 | 212.84% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-6.03% 4009/4961 |
-17.37% 4764/5312 |
- - |
- - |
| 2025 | -3.04% 3348/4813 |
-0.45% 2257/3635 |
-2.36% 3347/4076 |
6.41% 3527/4524 |
-6.25% 3687/4813 |
| 2024 | -4.44% 2239/3463 |
1.03% 904/2808 |
-9.68% 2385/3014 |
15.29% 1760/3129 |
-9.17% 2907/3463 |
| 2023 | -17.90% 1768/2656 |
2.34% 1373/2280 |
-13.31% 2208/2385 |
-1.53% 539/2515 |
-6.02% 1596/2655 |
| 2022 | -13.68% 337/2207 |
-16.92% 1161/1919 |
15.12% 180/2016 |
-9.70% 298/2113 |
-0.05% 1557/2208 |
| 2021 | -7.48% 1037/1822 |
-6.93% 1048/1255 |
3.84% 949/1330 |
-11.04% 1252/1466 |
7.62% 176/1822 |
| 2020 | 72.58% 62/1250 |
1.93% 140/1028 |
20.75% 262/1067 |
17.24% 112/1164 |
19.61% 73/1184 |
| 2019 | 66.30% 38/1092 |
42.65% 37/754 |
10.84% 3/804 |
1.70% 369/850 |
3.42% 837/918 |
| 2018 | -22.20% 231/834 |
- - |
- - |
- - |
-15.34% 604/691 |
| 2017 | 59.52% 4/714 |
- - |
- - |
- - |
- - |
| 2016 | 2.16% 86/605 |
- - |
- - |
- - |
- - |
| 2015 | 24.58% 95/575 |
- - |
- - |
- - |
- - |
| 2014 | 15.94% 196/237 |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 汇添富中证主要消费ETF VS. 长安沪深300非周期A(740101) |